Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

240 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Risk of Reactivation of Hepatitis B Virus Infection in Psoriasis Patients Treated With Biologics: A Retrospective Analysis of 20 Cases From the BIOBADADERM Database.
Sanz-Bueno J, Vanaclocha F, García-Doval I, Torrado R, Carretero G, Daudén E, Patricia Ruiz-Genao D, Alsina-Gibert MM, Pérez-Zafrilla B, Pérez-Rial G, Rivera R; members of the BIOBADADERM group. Sanz-Bueno J, et al. Actas Dermosifiliogr. 2015 Jul-Aug;106(6):477-82. doi: 10.1016/j.ad.2015.01.010. Epub 2015 Mar 13. Actas Dermosifiliogr. 2015. PMID: 25776200 Free article. English, Spanish.
Use of off-label doses is frequent in biologic therapy for moderate to severe psoriasis: A cross-sectional study in clinical practice.
Carrascosa JM, Garcia-Doval I, Pérez-Zafrilla B, Carretero G, Vanaclocha F, Daudén E, De la Cueva-Dobao P, Belinchón I, Alsina M, López-Estebaranz JL, Ferrán M, Torrado R, Rivera R, Carazo C, Barboza L, Ferrándiz C; BIOBADADERM Study Group. Carrascosa JM, et al. J Dermatolog Treat. 2015;26(6):502-6. doi: 10.3109/09546634.2015.1034070. Epub 2015 Apr 17. J Dermatolog Treat. 2015. PMID: 25886087
Development of clinical prediction models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis, based on the BIOBADADERM cohort.
García-Doval I, Pérez-Zafrilla B, Ferrandiz C, Carretero G, Daudén E, de la Cueva P, Gómez-García FJ, Herrera-Ceballos E, Belinchón-Romero I, Sánchez-Carazo JL, López-Estebaranz JL, Alsina M, Ferrán M, Torrado R, Carrascosa JM, Rivera R, Vanaclocha F; BIOBADADERM Study Group. García-Doval I, et al. J Dermatolog Treat. 2016;27(3):203-9. doi: 10.3109/09546634.2015.1088130. Epub 2015 Sep 25. J Dermatolog Treat. 2016. PMID: 26367799
Possible paradoxical occurrence of inflammatory arthritis in patients with psoriasis treated with biologics: findings in the Biobadaderm cohort.
Ruiz-Genao D, Perez-Zafrilla B, Lopez-Estebaranz JL, Belinchón-Romero I, Carrascosa JM, Ferrán M, Vanaclocha F, Herrera-Ceballos E, García-Doval I; Biobadaderm Study Group. Ruiz-Genao D, et al. Br J Dermatol. 2017 Mar;176(3):797-799. doi: 10.1111/bjd.14690. Epub 2016 Oct 17. Br J Dermatol. 2017. PMID: 27120993 No abstract available.
Should tumour necrosis factor antagonist safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective rheumatoid arthritis BIOBADASER and psoriasis BIOBADADERM cohorts.
García-Doval I, Hernández MV, Vanaclocha F, Sellas A, de la Cueva P, Montero D; BIOBADADERM and BIOBADASER study groups. García-Doval I, et al. Br J Dermatol. 2017 Mar;176(3):643-649. doi: 10.1111/bjd.14776. Epub 2016 Oct 3. Br J Dermatol. 2017. PMID: 27258623
Comparison of phenotype, comorbidities, therapy and adverse events between psoriatic patients with and without psoriatic arthritis. Biobadaderm registry.
Pérez-Plaza A, Carretero G, Ferrandiz C, Vanaclocha F, Gómez-García FJ, Herrera-Ceballos E, De la Cueva-Dobao P, Belinchón I, Sánchez-Carazo JL, Alsina M, López-Estebaranz JL, Ferrán M, Torrado R, Carrascosa JM, Llamas-Velasco M, Rivera R, Jiménez-Puya R, García-Doval I, Descalzo MA; Biobadaderm Study Group. Pérez-Plaza A, et al. J Eur Acad Dermatol Venereol. 2017 Jun;31(6):1021-1028. doi: 10.1111/jdv.14188. Epub 2017 Apr 12. J Eur Acad Dermatol Venereol. 2017. PMID: 28252811
Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm.
Belinchón I, Ramos JM, Carretero G, Ferrándiz C, Rivera R, Daudén E, De la Cueva-Dobao P, Gómez-García FJ, Herrera-Ceballos E, Sánchez-Carazo JL, López-Estebaranz JL, Alsina M, Ferrán M, Torrado R, Carrascosa JM, Llamas-Velasco M, Ortiz PL, García-Doval I, Descalzo MA; Biobadaderm Study Group. Belinchón I, et al. J Eur Acad Dermatol Venereol. 2017 Oct;31(10):1700-1708. doi: 10.1111/jdv.14314. Epub 2017 Jun 6. J Eur Acad Dermatol Venereol. 2017. PMID: 28485816
Characterization of Surgical Procedures in the Spanish Mohs Surgery Registry (REGESMOHS) for 2013-2015.
de Eusebio Murillo E, Martín Fuentes A, Ruiz-Salas V, Garcés JR, Miñano Medrano R, López-Estebaranz JL, Alonso-Alonso T, Rodríguez-Prieto MÁ, Delgado Jiménez Y, Morales V, Redondo Bellón P, Manubens-Mercadé E, Sanmartín-Jiménez O, Guillén Barona C, Cabeza R, Cano N, Toll-Abelló A, Navarro Tejedor R, Artola Igarza JL, Allende Markixana I, Alfaro Rubio A, Ciudad Blanco C, Vázquez-Veiga H, Barchino Ortiz L, Descalzo MA, García-Doval I. de Eusebio Murillo E, et al. Actas Dermosifiliogr. 2017 Nov;108(9):836-843. doi: 10.1016/j.ad.2017.04.018. Epub 2017 Aug 9. Actas Dermosifiliogr. 2017. PMID: 28802488 Free article. English, Spanish.
240 results